When is KNSA's latest earnings report released?
The most recent financial report for Kiniksa pharmaceuticals, ltd. (KNSA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KNSA's short-term business performance and financial health. For the latest updates on KNSA's earnings releases, visit this page regularly.
Where does KNSA fall in the P/E River chart?
According to historical valuation range analysis, Kiniksa pharmaceuticals, ltd. (KNSA)'s current price-to-earnings (P/E) ratio is 56.42, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of KNSA?
According to the latest financial report, Kiniksa pharmaceuticals, ltd. (KNSA) reported an Operating Profit of 19.77M with an Operating Margin of 9.78% this period, representing a growth of 202.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is KNSA's revenue growth?
In the latest financial report, Kiniksa pharmaceuticals, ltd. (KNSA) announced revenue of 202.13M, with a Year-Over-Year growth rate of 64.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does KNSA have?
As of the end of the reporting period, Kiniksa pharmaceuticals, ltd. (KNSA) had total debt of 9.5M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does KNSA have?
At the end of the period, Kiniksa pharmaceuticals, ltd. (KNSA) held Total Cash and Cash Equivalents of 165.6M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does KNSA go with three margins increasing?
In the latest report, Kiniksa pharmaceuticals, ltd. (KNSA) achieved the “three margins increasing” benchmark, with a gross margin of 89.6%%, operating margin of 9.78%%, and net margin of 7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess KNSA's profit trajectory and future growth potential.
Is KNSA's EPS continuing to grow?
According to the past four quarterly reports, Kiniksa pharmaceuticals, ltd. (KNSA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of KNSA?
Kiniksa pharmaceuticals, ltd. (KNSA)'s Free Cash Flow (FCF) for the period is 53.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 186.7% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of KNSA?
The latest valuation data shows Kiniksa pharmaceuticals, ltd. (KNSA) has a Price-To-Earnings (PE) ratio of 56.42 and a Price/Earnings-To-Growth (PEG) ratio of -2.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
